A GlaxoSmithKline spokesperson, Gwenan White, is quoted as saying the recall was issued after determining that one batch of H1N1 vaccine may be responsible for more allergic reactions than what is being seen with other batches.

The identified batch consists of 172,000 doses of the H1N1 vaccine.  The spokesperson declined to divulge how many doses had already been administered before the recall was issued.